Career Panel
Lee Goneau, Ph.D.
Lee completed his doctoral training in the department of Microbiology and Immunology at Western University in 2014 under the supervision of Drs. Gregor Reid and Jeremy Burton. Following his graduate studies, Lee completed a postdoctoral training program in Clinical Microbiology at the University of Toronto and became a Fellow of the Canadian College of Microbiologists in 2017. Lee previously worked as a clinical microbiologist with the Public Health Ontario Laboratory, overseeing testing of hepatitis, HIV, measles, mumps, rubella, and other viruses. Since 2019, Lee has been working as the National Director of Microbiology at Dynacare where he has led numerous initiatives, including implementation of SARS-CoV-2 testing, expanding the laboratory’s molecular diagnostics portfolio, and leveraging automation, artificial intelligence, and informatics to improve quality and patient care.
Biljana Todorovic, MSc., Ph.D.
Biljana completed her MSc at the University of Waterloo before coming to the department of Microbiology and Immunology at Western University for her doctoral training. She finished her doctoral training in 2013 under the supervision of Dr. Joe Mymryk. Following her PhD, she joined Boehringer Ingelheim as a Medical Science Liaison, launching multiple pharmaceutical products and working across different therapeutic areas including cardiology, endocrinology and nephrology for almost 9 years. Most recently, Biljana was an Associate Medical Director in Neuroscience within Medical Affairs at Jazz Pharmaceuticals and has recently embarked in a new commercial role at Jazz as an Associate Marketing Director in Neuroscience.
Wyatt Anderson, MSc.
Wyatt completed his MSc in the department of Microbiology and Immunology at Western University in 2020 under the supervision of Dr. Joe Mymryk. Wyatt is currently a Senior Research Associate in the Contract Assay Services department at StemCell Technologies in Vancouver, BC. In his current position, Wyatt works with R&D to develop new biological models and technologies. This is predominantly revolving around the development of tissue models to be used in future assays, like the development and cultivation of 3D intestinal organoids for testing or further development into mature membranes. These tissue models are then used to develop assays, like the recently launched Intestinal Viability assay.
